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Available online 11 August 2004660Uncontrolled insertion of gene transfer vectors into the human genome is raising significant safety
concerns for their clinical use. The wild-type adeno-associated virus (AAV) can insert its genome at a
specific site in human chromosome 19 (AAVS1) through the activity of a specific replicase/integrase
protein (Rep) binding both the AAVS1 and the viral inverted terminal repeats (ITRs). AAV-derived
vectors, however, do not carry the rep gene and cannot maintain site-specific integration properties.
We describe a novel hybrid vector carrying an integration cassette flanked by AAV ITRs and a tightly
regulated, drug-inducible Rep expression cassette in the framework of a high-capacity, helper-
dependent adenoviral (Ad) vector. Rep-dependent integration of ITR-flanked cassettes of intact size
and function was obtained in human primary cells and cell lines in the absence of selection. The
majority of integrations were site specific and occurred within a 1000-bp region of the AAVS1.
Genome-wide sequencing of integration junctions indicates that nonspecific integrations occurred
predominantly in intergenic regions. Site-specific integration was obtained also in vivo, in an AAVS1
transgenic mouse model: upon a single tail vein administration of a nontoxic dose of Ad/AAV
vectors, AAVS1-specific integrations were detected and sequenced in DNA obtained from the liver of
all animals in which Rep expression was induced by drug treatment. Nonrandom integration of
double-stranded DNA can therefore be obtained ex vivo and in vivo by the use of hybrid Ad/AAV
vectors, in the absence of toxicity and with efficiency compatible with gene therapy applications.Key Words: gene transfer, viral vectors, adeno-associated virus, adenovirus,
site-specific integrationINTRODUCTION
Gene therapy of many genetic and acquired disorders
requires stable integration of appropriately regulated
transgenes in human somatic cells. Gene transfer vectors
derived from RNA oncoretroviruses or lentiviruses inte-
grate at high efficiency in the human genome, but in an
almost random fashion and with a preference for active
genes [1,2]. Retroviral vectors have limited genome
capacity, do not easily accommodate introns or complex
regulatory elements, and are ill suited to in vivo use.
Adenoviral (Ad) or adeno-associated viral (AAV) DNA
vectors, on the other hand, do not normally integrate or
do so sporadically and with unpredictable configurations
[3]. Development of an integrating, large-capacity DNA
viral vector is still an unmet goal of gene transfer
technology.
Development of helper-dependent (HD), fully deleted
Ad vectors has significantly reduced the limitationsassociated with first-generation vectors, such as acute
toxicity, inflammatory and cytotoxic immune response
against the viral proteins, and short-term persistence of
gene expression [4–10]. AAV vectors have also been used
to mediate long-term gene expression in nondividing
cells. The wild-type AAV genome is a linear, single-
stranded DNA filament of 4.7 kb, which contains at both
ends a 145-base inverted terminal repeat (ITR), encoding
the origin of replication and the packaging signal, and
two AAV-specific genes, rep and cap [11]. rep encodes four
overlapping proteins of 78, 68, 52, and 40 kDa, generated
by alternative splicing of transcripts from two alternative
promoters. The ITRs and either Rep78 or Rep68 are
sufficient for replication of the AAV genome and medi-
ating its integration into a specific site (AAVS1) on
human chromosome 19q13.3–qter [12–14]. However,
due to the very limited packaging size of AAV particles,
AAV vectors are deleted of all viral genes and have1525-0016/$30.00
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property of the wild-type virus. AAV vectors maintain a
residual capacity for ITR-mediated integration in some
target cells (e.g., liver), although at low efficiency and
with virtually no site specificity [15–18]. AAV ITRs and
Rep functions have been previously incorporated into
hybrid, large-capacity viral vectors, such as baculoviral
and HSV-1 amplicon vectors [19–21], or into a split Ad/
AAV vector system, in which an AAV ITR-flanked
integration cassette and a Rep78/68 expression cassette
were carried by two different HD-Ad vectors [22]. How-
ever, the inhibitory effect of Rep on viral replication [23–
25] prevented or significantly affected the production of
Ad and HSV-1 vectors incorporating all the elements of
the AAV integration machinery [20–22].
In this report, we describe the development of single
hybrid Ad/AAV vectors carrying a double reporter gene
integration cassette flanked by AAV ITRs and tightly
regulated, drug-inducible Rep expression cassettes. The
hybrid vectors were successfully packaged and purified at
a titer of N109 transducing units/ml. Upon infection at
low multiplicity of susceptible human primary cells and
cell lines, Rep-dependent, AAVS1-specific integration of
ITR-flanked cassettes of intact size and function was
obtained with an efficiency proportional the level of Rep
expression and in the absence of cell selection. Site-
specific integration was studied also in vivo, in transgenic
mice carrying one copy of a 3.5-kb fragment of the AAVS1
on the X chromosome. Upon a single tail vein admin-
istration of a nontoxic dose (2  108 transducing units) of
Ad/AAV vectors, AAVS1-specific integrations were map-
ped and sequenced in DNA obtained from the liver of
animals in which activation of Rep expression was
induced by drug treatment. Site-specific integration of a
double-stranded DNA transgene into the human genome
can therefore be obtained ex vivo and in vivo by a single
administration of a HD-Ad/AAV vector.
RESULTS
Construction of HD-Ad/AAV Hybrid Vectors
To overcome the negative effects of Rep on packaging
and genetic instability of AAV ITR-containing Ad
genomes, we developed a series of alternative con-
structs in which the expression of Rep78 was con-
trolled by a tetracycline-inducible activation/repression
system [26]. The prototype vector (AR1) contained an
AAV ITR-flanked integration cassette with two different
reporter genes, the green fluorescent protein (GFP) and
a truncated version of the p75 low-affinity nerve
growth factor receptor (DLNGFR) under the control of
the phosphoglycerokinase (PGK) and the SV40 early
promoter, respectively, cloned into the STK-120 HD-Ad
backbone (Fig. 1). Four different vectors were derived
from AR1 in the STK-119 backbone by adding Rep78
expression cassettes with different types of regulation.MOLECULAR THERAPY Vol. 10, No. 4, October 2004
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tors contained, in opposite transcriptional orientation,
a Rep78 expression cassette under the control of the
cytomegalovirus (CMV) immediate-early minimal pro-
moter (53) linked to the bacterial tet operator (tetO-
CMV) and a bicistronic expression cassette in which
the tetracycline-controlled reverse transcriptional acti-
vator (rtTA) and transcriptional silencer (tTS) genes
were expressed under the control of the CMV pro-
moter/enhancer (675) and an internal ribosomal
entry site (IRES) in either configuration (TA/TS or TS/
TA) (Fig. 1). In the absence of the inducer, the
tetracycline analogue doxycycline (Dox), the tTS pro-
tein binds to, and represses transcription from, the
tetO-CMV element controlling Rep expression, while in
the presence of Dox the rtTA protein allows activation
of tetO-CMV transcription at high levels. The AR1-
CMVRepTS vector contained only the tTS gene under
the control of a CMV promoter, while in the AR1-
TKRepTS vector the Rep78 gene was under the control
of the minimal promoter (81) of the HSV-1 thymi-
dine kinase gene (TK) linked to the tetO element (tetO-
TK) (Fig. 1). The control vector, CMVRep, contained
only a Rep78 expression cassette driven by the CMV
promoter/enhancer in the STK-120 backbone (Fig. 1).
Control of Rep78 Expression
We assessed expression and regulation of Rep78 for all
vectors by transfecting 293Cre4 cells with the vector
plasmids in the presence and absence of Dox. We
harvested the cells 24 or 48 h after transfection and
analyzed their nuclear extracts by Western blotting and
using a rabbit anti-Rep polyclonal antiserum. Cells trans-
fected with the vectors expressing both rtTA and tTS (AR1-
CMVRepTA/TS and AR1-CMVRepTS/TA) accumulated
high levels of Rep78, independent of the configuration
of the rtTA–tTS expression cassette and the presence of the
inducer (not shown). In contrast, in cells transfected with
the vectors expressing only the tTS suppressor (AR1-
CMVRepTS and AR1-TKRepTS), basal Rep78 expression
was very well controlled and induced by Dox 48 h
posttransfection at levels comparable with those obtained
by an unmodified CMV promoter (Fig. 2A). These vectors
were therefore chosen for further analysis.
Packaging of the Ad/AAV Hybrid Vectors
We produced the HD-Ad vectors by transfection/infec-
tion of the 293Cre4 cell line, as previously described [22].
After five serial passages of viral amplification, the
integrity of the episomal Ad vectors was controlled by
Southern blot analysis of Hirt DNA extracted from crude
lysates of the packaging cells. Both the AR1-CMVRepTS
and AR1-TKRepTS viruses yielded the predicted restric-
tion fragments when grown in the absence of Dox, while
they rearranged when grown in the presence of Dox
(results not shown). Both viruses correctly expressed the661
FIG. 1. Schematic representation of vector
structures. Expression cassettes were inserted
into the pSTK120 (25.8 kb) or pSTK119
(23.3 kb) HD-Ad plasmids. The prototype
vector, AR1, contains an AAV ITR-flanked
integration cassette in which expression of
GFP and DLNGFR is driven by a PGK and a
SV40 promoter, respectively. The CMVRep
vector contains an AAV Rep78 ORF under the
control of the CMV immediate-early
enhancer/promoter (675). In the other
vectors, the AAV integration cassette is
combined with an inducible Rep expression
cassette, in which the Rep78 ORF is driven by
a minimal CMV (53) or TK (81) promoter
controlled by a bacterial tet operator (tetO)
sequence, and a CMV-driven expression
cassette for the tetracycline-controlled
reverse transcriptional activator (TA) and
transcriptional silencer (TS) genes in either
configuration with respect to an internal
ribosomal entry site (IRES) element (AR1-
CMVRepTA/TS and AR1-CMVRepTS/TA) or
the TS only (AR1-CMVRepTS and AR1-
TKRepTS).
ARTICLE doi:10.1016/j.ymthe.2004.07.003reporter genes (GFP and DLNGFR), as demonstrated by
FACS analysis of infected HeLa cells, and Rep78, as
indicated by a rescue and replication assay carried out
on 293 cells superinfected with a first-generation Ad
vector (not shown).
Medium-scale preparations of AR1-CMVRepTS and
AR1-TKRepTS were comparable in terms of total viral
particles (1011 vs 8.3  1010), while the AR1-TKRepTS
preparation was better in terms of transducing units
(1.3  109 vs 2  108), virions per packaging cell (415 vsFIG. 2. Western blot analysis of Rep expression in crude
nuclear extracts. (A) 293Cre4 packaging cells trans-
fected with CMVRepTS and TKRepTS, in the presence
(+) or absence () of Dox, and CMVRep. Signals were
normalized with a monoclonal antibody against the
chromatin-associated nuclear protein HMG1. (B) HeLa
cells mock infected (mock) or infected with AR1-
CMVRepTS or AR1-TKRepTS at an m.o.i. of 5 and
analyzed after 48 h of culture FDox. (C, D) Human
primary keratinocytes and amniocytes mock infected
(mock) or infected with AR1-TKRepTS at an m.o.i. of
20 and analyzed after 5 days of culture FDox.
MOLECULAR THERAPY Vol. 10, No. 4, October 2004662
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different activity of the two tetO-controlled minimal
promoters was demonstrated in HeLa cells infected at
low (5 tu/cell) multiplicity of infection (m.o.i.) and
maintained for 48 h in the presence or absence of Dox.
Expression of Rep78 was assessed by Western blot
analysis of crude nuclear extracts. Basal expression of
Rep78 was low from the tetO-CMV promoter and
virtually undetectable from the tetO-TK promoter (Fig.
2B). Expression of Rep78 was induced by Dox in bothy
ARTICLEdoi:10.1016/j.ymthe.2004.07.003cases, although at much higher levels from the tetO-
CMV promoter (Fig. 2B).
Site-Specific Integration of the AAV ITR-Flanked
Cassette in HeLa Cells
We infected HeLa cells with the AR1-TKRepTS vector
at an m.o.i. of 20, cultured them for 4 weeks FDox,
and scored them for the expression of GFP and
DLNGFR. Of the cells cultured with Dox, 1.5–2.0%
maintained reporter gene expression, while cells cul-
tured without Dox, or transduced with the control
Rep AR1 vector, scored negative already 3 weeks after
infection. To analyze vector integrations, we FACS-
sorted GFP+/DLNGFR+ HeLa cells and cloned them by
limiting dilution. We extracted genomic DNA from all
clones and analyzed them by Southern blotting after
restriction with AccI, which releases a 3.1-kb fragment
encompassing most of the chromosome 19 AAVS1
site. Hybridization with an AAVS1-specific probe
showed a size shift of the 3.1-kb band in 9 of 17
(53%) independent HeLa clones, indicating rearrange-
ment of the AAVS1 region in at least one chromo-
some 19 (Fig. 3). The rearranged bands hybridized also
to a GFP-specific probe in 7 of the 9 clones,MOLECULAR THERAPY Vol. 10, No. 4, October 2004
Copyright C The American Society of Gene Therapyindicating the integration of the AAV ITR-flanked
cassette in the AAVS1 region. Further restriction
analysis indicated that the AAV ITR-flanked cassette
had integrated as a monomer or a dimer in the
AAVS1 site and conserved an intact structure in all
cases (not shown). In 2 clones (45 and 57 in Fig. 3),
the AAVS1 site showed a rearranged band that did not
hybridize to the ITR probe, indicating Rep-mediated
disruption of the AAVS1 region in the absence of
integration. Conversely, 10 of 17 clones showed bands
corresponding to intact AAV ITR-flanked cassettes
integrated elsewhere in the genome. Two clones (18
and 31 in Fig. 3) showed both AAVS1-specific and
nonspecific integrants.
To verify whether insertion of functional rep genes
occurred together with integration of the AAV ITR-
flanked cassette, we carried out a rescue and repli-
cation assay on GFP+/DLNGFR+ HeLa clones super-
infected with wild-type Ad5 virus in the presence of
Dox. Hirt DNA was extracted from infected cells and
analyzed by Southern blotting with a GFP-specific
probe. We detected no band corresponding to the
replicated form of the AAV ITR-flanked integration
cassette in any of the HeLa clones, indicating that noFIG. 3. Southern blot analysis of 17 independent HeLa
cell clones (numbered) derived from a bulk culture of
HeLa cells transduced with AR1-TKRepTS and grown
in the presence of Dox. 20 Ag of genomic DNA was
digested with Acc I and hybridized to an AAVS1-
specific probe (left). The 3.1-kb AccI AAVS1 intact
genomic fragment is indicated by an arrow. The same
blots were rehybridized to a GFP probe to detect the
ITR-flanked integration cassette (right). Rearranged
bands hybridizing to both probes, and corresponding
to AAVS1 site-specific integrations, are indicated by
asterisks. HeLa clones containing site-specific inte-
grants are indicated in bold. In all blots, the first lane
contains DNA from mock-transduced cells and the last
lane a size marker.
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FIG. 4. Analysis of the AAV ITR-AAVS1 junctions in human primary cells infected with AR1-CMVRepTS and AR1-TKRepTS. (A) PCR amplification of ITR-AAVS1
junctions from amniocyte DNA by AAV ITR- and AAVS1-specific nested primers (c and d in B) hybridized to AAVS1 (left) and ITR (right) probes. (B) Schematic
representation of the 3.5-kb AAVS1 locus. Locations of Rep-binding (RBS) and terminal resolution (TRS) sites are indicated. a–f indicate AAVS1-specific primer pairs
Integration hot spots into keratinocyte, amniocyte, and HeLa cell DNA are indicated by circles. (C) Sequences of integration junctions in DNA from amniocyte
transduced by AR1-CMVRepTS (sequences 2–4) or AR1-TKRepTS (5–10) and from keratinocytes transduced with AR1-TKRepTS (11–13) or AR1-CMVRepTS (14, 15)
Sequence 1 is the junction in HeLa clone 41 used as a standard in the quantitative PCR assay (Fig. 5). Breakpoints on both ITR and AAVS1 are indicated. The ITR RBS
and TRS are indicated in bold. Sequence insertions at the junctions between ITR and AAVS1 are in lowercase. Partial, inverted sequences of ITR origin are in italic
ARTICLE doi:10.1016/j.ymthe.2004.07.003
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genomes (not shown).
Site-Specific Integration in Human Primary Cells
We infected early passage amniocytes and keratinocytes
with AR1, AR1-CMVRepTS, and/or AR1-TKRepTS at an
m.o.i. of 20 and grew them for 5 days in the presence or
absence of Dox. We tested for induction of Rep78
expression by Western blotting of crude nuclear extracts
5 days after infection (Figs. 2C and 2D). We extracted high-
molecular-weight DNA from these cells and analyzed it by
nested-set PCR with AAVS1- and AAV ITR-specific primers
(c and d in Fig. 4B). As shown in Fig. 4A, DNA bands
recognized by both the AAVS1 and the AAV ITR probes
were amplified from amniocytes transduced by the AR1-
CMVRepTS vector in the presence and absence of Dox and
by the AR1-TKRepTS vector only in the presence of Dox
(Fig. 4A). We detected no signal in cells transduced by the
control Rep AR1 vector (not shown).
We analyzed the distribution of integrants throughout
the AAVS1 region by PCR using three couples of nested
primers annealing to different positions within AAVS1 (a
and b at nt 526–615, c and d at nt 1175–1349, and e and f
at nt 1612–2089, see Fig. 4B). Specific DNA bands (200 to
700 bp long) were amplified from all cells only by the c +
d and e + f sets of primers (not shown).
To characterize further the integrations, we cloned
and sequenced PCR-amplified bands. Analysis of the
integration junctions showed that the insertions clus-
tered within a 1-kb region of the AAVS1 (nucleotides 987
to 1996), downstream of the Rep-binding site (RBS;
nucleotides 398–413) (Fig. 4C). We detected two major
breakpoints in the AAV ITR, around nucleotides 4600 (10
insertions) and 4560 (5 insertions). Ten breakpoints
occurred downstream of the ITR RBS (nucleotides 4565–
4587), 2 within the RBS, and 3 between the RBS and the
terminal resolution site (TRS; nucleotides 4547–4552)
(Fig. 4C). We observed DNA insertions of variable lengthTABLE 1: Distribution of Rep-mediated, non-site-specific integ
transduced by AR1-CMVRe
ID ITR breaks Chromo
1 nt 4597 1q25.1; nt 17
2 nt 4624 2p21; nt 45
3 nt 4601 3p21.1; nt 53
4 nt 4597 3p12.3; nt 77
5 nt 4596 3p12.3; nt 77
6 nt 4598 6q16.3; nt 10
7 nt 4593 10q26.2; nt 12
8 nt 4599 12p11.2; nt 27
9 nt 4603 12q21.3; nt 86
10 nt 4593 Xq28; nt 14
11 nt 4593 Xq28; nt 14
12 nt 4623 Xq21.1; nt 76
The nucleotide position of the breakpoint on the AAV ITR and the chromosomal location, nuc
indicated.
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Fig. 4C). Interestingly, 3 of these insertions correspond to
partial AAV ITR sequences in reverse orientation (in italic
in 2, 11, and 12 in Fig. 4C).
To provide an estimate of the frequency of Rep-
mediated, site-specific integration we carried out a
quantitative, real-time PCR assay of DNA extracted from
amniocytes and keratinocytes transduced by both vectors
at an m.o.i. of 20 and grown for 5 days in the presence or
absence of Dox. The analysis was carried out with a
primer annealing to nt 4522–4548 in the right-side ITR of
the integration cassette (17s) and a primer and an
internal fluorescent probe annealing to nt 1612–1593 (e
in Fig. 4) and 1562–1583 of the AAVS1, respectively. We
used DNA from a HeLa clone (No. 41) with an integration
cassette inserted as a dimer at position 1282 of the AAVS1
as a standard of 2 integrated copies per genome in 100%
of the cells. The estimated proportion of cells harboring
an AAVS1-specific integration ranged from 0.1% in
keratinocytes transduced with AR1-TKRepTS to 16.0%
in amniocytes transduced with AR1-CMVRepTS. No site-
specific integration was detectable in cells transduced
with the AR1-TKRepTS vector in the absence of Dox.
Since the couple of primers used to run the real-time PCR
assay detects only a subset of the integration sites
observed by sequence analysis (Fig. 4) and only one
orientation of the integrated cassette, these should be
considered only as relative estimates, indicating a direct
correlation between integration efficiency and Rep
expression levels in the transduced cells (see Fig. 2).
Analysis of Non-Site-Specific Integrations in Human
Primary Cells
To analyze the Rep-mediated, non-AAVS1-specific inte-
grations of the AAV ITR-flanked cassette in human
primary cells, we subjected genomic DNA extracted from
keratinocytes transduced by the AR1-CMVRepTS vector
to linker-mediated (LM) nested PCR using a combinationration sites in the genome of human primary keratinocytes
pTS in presence of Dox
some location Target
1222634–171222654 Intergenic
289588–45289691 Intergenic
429734–53429817 Intergenic
984746–77984836 Intergenic
984738–77984837 Intergenic
3924210–103924365 Intergenic
9830641–129830664 Intergenic
683849–27683908 Intergenic
363480–86363554 NM003622, introns 4–5
8325730–148325840 Intergenic
8326006–148326150 Intergenic
115269–76115177 Intergenic
leotide position, and length of amplified sequence at the breakpoints on genomic DNA are
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ARTICLE doi:10.1016/j.ymthe.2004.07.003of ITR- and linker-specific primers, followed by cloning
and sequencing of the PCR products. Twelve of 20
sequences met our validity criteria (presence of a pri-
mer-containing ITR sequence and a genomic sequence
featuring a unique best hit with z95% identity to the
human genome), and all were unambiguously mapped by
Ensembl BLAST analysis on chromosomes 1, 2, 3, 6, 10,
12, and X (Table 1). Only one of these sequences
corresponded to an integration into a known gene,
introns 4–5 of the PPFIBP1 gene on chromosome
12p11.23 (NM003622), indicating that Rep-mediated
integration has a general preference for intergenic
regions. We observed inverted ITR sequences at the
vector–cellular DNA junction in the majority of theseFIG. 5. Site-specific integration in the liver of AAVS1 transgenic mice upon sys
Immunohistochemical analysis of GFP expression in the liver of mice injected with
section from a mock-infected mouse is shown for comparison. (B) AAVS1-specific
(mouse 1) or mice injected with the Ad/AAV vectors FDox treatment (mice 2–
amplification products were fractionated on a 1.5% agarose gel (top) and hybrid
from HeLa clone 41 was used as positive control. (C) Sequences of integratio
CMVRepTS (mice 2 and 4) or AR1-TKRepTS (mice 7 and 9) and treated with Do
indicated in bold.
666insertions. We obtained no valid sequence by LM-PCR
analysis of DNA extracted from keratinocytes transduced
by the Rep AR1 vector.
Site-Specific Integration in AAVS1 Transgenic Mice
in Vivo
To analyze the ability of the hybrid vectors to mediate
site-specific integration in vivo, we injected 2  108
transducing units of either AR1-TkRepTS or AR1-
CMVRepTS into the tail vein of two groups of transgenic
mice (four mice per group) carrying 1 copy of a 3.5-kb
fragment of the AAVS1 in the X chromosome [27]. Half
of the mice were given Dox in the drinking water from
day 4 to +12. We injected control mice with 2  108 totemic administration of AR1-CMVRepTS, AR1-TKRepTS, and AR1 vectors. (A
AR1 (109 tu), AR1-CMVRepTS (2  108 tu), and AR1-TKRepTS (2  108 tu). A
PCR assay on genomic DNA extracted from the liver of a mock-infected mouse
5 and mice 7–10) or with the AR1 control vector (mouse 6). One-fifth of the
ized to AAVS1-specific (middle) and ITR-specific (bottom) probes. PCR of DNA
n junctions obtained from the liver of mice systemically injected with AR1
x. Breakpoints on both ITR and AAVS1 are indicated. The ITR RBS and TRS are
MOLECULAR THERAPY Vol. 10, No. 4, October 2004
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ARTICLEdoi:10.1016/j.ymthe.2004.07.003109 tu of the Rep AR1 vector or saline. We sacrificed all
the mice 12 days after injection and analyzed their livers
by immunohistochemistry for GFP expression (Fig. 5A).
Transduction efficiency in liver hepatocytes averaged 3
(lower dose) and 30% (higher dose) in mice infected with
AR1 and 3% in mice infected with AR1-TkRepTS or AR1-
CMVRepTS. We detected AAVS1-specific integration by
PCR with a standard set of nested primers (ITR primers
and c + d genomic primers, see Fig. 4) in genomic DNA
extracted from the liver of all mice infected with AR1-
TkRepTS and AR1-CMVRepTS and treated with Dox (Fig.
5B, mice 2, 4, 7, and 9). The PCR was always negative in
the DNA extracted from animals not exposed to Dox
(Fig. 5B, mice 3, 5, 8, and 10), mock infected (Fig. 5B,
mouse 1), or infected with the Rep AR1 vector (Fig. 5B,
mouse 6).
To confirm the existence of AAVS1-specific integrants,
we cloned and sequenced the PCR products. As shown in
Fig. 5C, AAVS1-specific sequences were obtained from all
mice, with breakpoints within or downstream of the RBS
of the AAV ITR and between nucleotides 776 and 1044 in
the AAVS1 sequence. No extra nucleotide was detected at
the breakpoints (Fig. 5C). To provide a relative estimate
of the frequency site-specific integration, we carried out a
quantitative, real-time PCR assay on the DNA extracted
from the livers of mice 2, 4, 6, 7, and 9, using nested
primers (ITR primers and c + d genomic primers) and an
internal fluorescent probe annealing to nt 1125–1141 of
the AAVS1 (Fig. 6). We used plasmid DNA carrying anFIG. 6. Real-time PCR assay for quantification of AAVS1-specific integration in t
Arrows indicate ITR- and AAVS1-specific primers. The probe (1125–1141 in the
dilutions (106–102 copies) of plasmid DNA carrying an ITR–AAVS1 junction cloned
integration of the AR1-CMVRepTS, AR1-TKRepTS, and control AR1 vectors as co
MOLECULAR THERAPY Vol. 10, No. 4, October 2004
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(Fig. 5) as standard. Estimated integration frequencies
ranged from 0.2 to 2.0% of haploid liver genome (Fig. 6).
DISCUSSION
Random integration of gene transfer vectors is becoming a
major concern for clinical application of gene therapy.
Both retroviral and lentiviral vectors were shown to
integrate preferentially into active genes [1,2], and the
occurrence of T cell leukemia in patients treated by gene
therapy for severe combined immunodeficiency has been
correlated with the integration of a retroviral vector into a
T cell proto-oncogene [28]. For therapy of non-life-threat-
ening disorders, an increased risk of cancer could result in
an ethical barrier to the use of randomly integrating
vectors. In this report, we describe the development of a
new generation of hybrid DNA vectors that combine the
large capacity and infectivity of adenoviral vectors with
the ability of the AAV Rep protein to direct the integration
of AAV ITR-flanked sequences at specific sites into the
human genome.
A major difficulty in building viral vectors containing
Rep expression cassettes is the negative effect of Rep on
viral replication [24,25], which prevents packaging or
reduces titers to values unacceptably low for practical
use. To overcome these problems, we have developed a
tight, drug-inducible transcriptional regulation system
based on a minimal promoter under the control of thehe transgenic mouse livers. (A) Schematic map of an integrated ITR cassette.
AAVS1) is indicated by a bar. (B) Standard curves were generated using serial
from the liver of mouse 2 (Fig. 5). The table shows the efficiency of site-specific
pies per cell and % of haploid liver genome.
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ARTICLE doi:10.1016/j.ymthe.2004.07.003tetO element and a constitutively expressed tTS suppres-
sor. This combination allowed efficient packaging of a
single HD-Ad vector containing both a Rep expression and
an AAV ITR-based integration cassette. Drug-induced
activation of Rep allowed us to integrate intact copies of
the ITR-flanked cassette into the AAVS1 site in human
primary cells, at very low (1 or 2) copy number, in the
absence of selective pressure and with efficiency higher
than previously reported for other Rep-based integration
systems. In an animal model of targeted gene delivery, an
AAVS1 transgenic mouse, we could demonstrate AAVS1-
specific integration in liver DNA 12 days after adminis-
tration of a single dose of Ad/AAV vector transducing less
than 5% of the hepatocytes. Drug-induced, site-specific
integration of medium-size transgenes can therefore be
obtained ex vivo and in vivo by administration of nontoxic
doses of hybrid Ad/AAV vectors containing a drug-
inducible Rep expression cassette.
Sequencing of the ITR–AAVS1 junctions showed that
the Rep-mediated integration is remarkably precise both
in vitro and in vivo, without significant loss or rearrange-
ment of either ITR or genomic sequences at the break-
points. The ITR sequences were interrupted downstream
or within the Rep-binding sequence, as observed for wild-
type AAV integration. In some of the breakpoints cloned
from primary cells transduced in vitro, we observed the
insertion of small, inverted sequences of ITR origin at the
vector–cellular DNA junction. Scrambled alignments of
vector and genomic sequences were previously observed
at the junction of AAV vectors into mouse liver DNA and
interpreted as the consequence of Rep-independent
replication of the single-stranded AAV vector genome
during integration [29], most likely mediated by a tran-
scription-coupled, double-strand break DNA repair mech-
anism leading to preferential integration into transcribed
chromatin regions [30,31]. Our data would indicate that
DNA replication is strictly associated with integration
also in the case of Rep-mediated integration starting from
a double-stranded template.
A LM-PCR-based cloning and sequencing approach
confirmed the existence of non-AAVS1-specific integra-
tion sites in primary cells and indicated their almost
random distribution with a preference (11 of 12) for
intergenic, nontranscribed regions. Interestingly, 2 of
these integrations occurred at a distance of 8 bp from
each other on chromosome 3 and 2 at a distance of 276
bp on chromosome X. Furthermore, inverted ITR sequen-
ces such as those observed at the ITR–AAVS1 junctions
were detected also in the majority of the insertions
outside the AAVS1. These findings indicate that Rep
played a role in mediating both AAVS1-specific and
nonspecific integrations and suggest the existence of
additional, less frequent preferential sites in the human
genome. Although the small size of the sample does not
allow us to draw statistically significant conclusions, the668observed preference for nontranscribed regions appears
opposite to that observed for recombinant AAV vectors in
a sample of genomic integrations of comparable size [30].
A possible explanation for this difference is that Rep-
mediated integration starting from a double-stranded
template would no longer require coupling to the tran-
scriptional machinery, as postulated in the case of single-
stranded AAV templates [31].
The efficiency of AAVS1-specific integration was
proportional to the level of Rep78 expressed by the
vector, both in vitro and in vivo. Higher Rep levels,
obtained for instance by the use of more potent pro-
moters, would probably further increase integration
efficiency, although there is a trade-off caused by the
Rep-induced toxicity for the target cells. Constitutive
expression of Rep was reported to induce caspase-3-
mediated, p53-independent apoptosis and cell cycle
arrest in mammalian cells [32]. Our study indicates that
in ~10% of stably transduced HeLa clones the AAVS1
locus is rearranged even in the absence of an integrated
cassette. This is probably due to the ability of Rep to bind
to the RBS in AAVS1, induce nicking at the nearby TRS,
and start unscheduled DNA replication before binding to,
replicating, and eventually integrating an ITR-containing
genome [33]. In the presence of exceedingly high or
prolonged synthesis of Rep, the AAVS1 site could become
a hot spot of chromosome fragility or genetic recombi-
nation in transduced cells, an obviously undesirable side
effect of a Rep-based integration system. Drug-controlled
Rep expression is expected to reduce these potential
genotoxic effects, an additional safety characteristic of
our hybrid vectors.
Expression of Rep, a likely immunogenic protein,
could potentially elicit a cytotoxic immune response
against cells transduced in vivo by a Rep-expressing
vector. The drug-controlled expression system is expected
to reduce the immunogenicity of Rep to a minimum,
although it introduces an additional immunogenic fac-
tor, the constitutively expressed Tet repressor protein.
The immunogenic potential of the Tet repressor is a
controversial issue, although it is conceivable that in cells
or tissues in which episomal Ad vectors persist for long
time (liver, for example) this might eventually turn out to
be a problem. Anti-Rep and anti-Tet immune responses
therefore need to be addressed in specific animal models
for each vector delivery route.
Adenovirus-based integrating vectors could find prac-
tical application in both ex vivo and in vivo gene transfer
protocols. The large capacity of the Ad vector backbone
allows the incorporation of large genes and complex
regulatory systems into the vectors, a current limitation
of retroviral vector technology. A high proportion of
site-specific integration and a general preference for
nontranscribed regions would reduce both the risk of
insertional oncogenesis and the problem of position-MOLECULAR THERAPY Vol. 10, No. 4, October 2004
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sion. The relatively low vector titers obtained with the
currently available HD-Ad packaging system still appear
as a limitation for the in vivo use of Ad/AAV hybrid
vectors. However, progress is being rapidly made in the
Ad vector field and should allow these potential limi-
tations to be overcome in the near future.
MATERIALS AND METHODS
Cell culture. HeLa, HepG2, 293 (ATCC), and 293Cre4 (Merck, West Point,
PA, USA) cell lines were propagated in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum (Hyclone). Human
primary amniocytes were obtained from prenatal amniocentesis and
maintained in Chang’s medium B (Irvine Scientific, Santa Ana, CA, USA).
Human primary keratinocytes were isolated from skin biopsies and
maintained in Defined Keratinocyte-SFM (Gibco Invitrogen Co., UK).
Construction and packaging of the HD-Ad/AAV hybrid vectors. The
pSTK120 HD-Ad vector backbone was used to generate the pCMVRep
vector, carrying a Rep78 cDNA under the control of the CMV immediate
early promoter/enhancer sequence (675 to +41), and the pAR1 vector,
containing a GFP expression cassette (pEGFP-C3; Clontech, Palo Alto, CA,
USA) driven by the human PGK promoter and a cDNA coding for a carboxy-
terminal truncation of the human p75 low-affinity nerve growth factor
receptor (DLNGFR) under the SV40 early promoter, all flanked by AAV ITRs
(3.8 kb). The pSTK119 backbone was used to generate vectors containing
both the AAV ITR-flanked integration cassette and the Rep78 regulated
expression systems. In the pAR1-CMVRepTA/TS and pAR1-CMVRepTS/TA
vectors, the Rep78 gene was driven by a CMV immediate early minimal
promoter (53 to +41) fused to the bacterial tet operator (tetO-CMV), while
the two Dox-regulated transcription factors rtTA and tTS (from the pTet-On
and pTet tTS plasmids; Clontech) were inserted in either configuration in a
CMV promoter-driven bicistronic transcriptional unit containing the IRES
of the encephalomyocarditis virus, derived from the pIRESneo expression
vector (Clontech). The TA/TS and TS/TA cassettes were cloned in opposite
transcriptional orientations with respect to the tetO-CMVRep78 cassette. In
the pAR1-CMVRepTS and pAR1-TKRepTS plasmids, the Rep78 gene was
under the control of the tetO-CMV promoter or a minimal HSV-TK
promoter (81 to +52) linked to the tetO element (tetO-TK), respectively.
Both plasmids contained a CMV-driven tTS expression cassette in opposite
transcriptional orientation with respect to the Rep78 cassettes. Rescue and
amplification of the HD-Ad viruses were carried out by transfection of
293Cre4 and infection with AdH14 first-generation helper virus (Merck,
West Point, PA, USA), as previously described [22]. Infectious particle titer
was established on HeLa cells.
Analysis of Rep78 expression. Nuclear extracts were prepared by lysing
cells in 10 mM Hepes, pH 7.9, 600 mM NaCl, 1.5 mM MgCl2, 0.1 mM EDTA,
0.5 mM DTT, and a standard cocktail of protease inhibitors, run in 5-Ag
aliquots on 8% polyacrylamide/SDS gels, electrotransferred to nitrocellu-
lose membranes, and incubated with an anti-Rep polyclonal rabbit
antiserum (a gift from Carlo Toniatti) in PBS + 0.1% Tween 20 for 1 h at
room temperature. Rep78-specific bands were visualized by a chemilumi-
nescence kit (ECL Amersham Pharmacia Biotech, UK).
Southern blot analysis. High-molecular-weight DNA was extracted from
5  106 HeLa cells, digested in 20-Ag aliquots with AccI, run on a 0.8%
agarose gel, transferred to a nylon membrane (Duralon; Stratagene, TX,
USA), and hybridized to AAVS1- and GFP-specific probes according to
standard methods.
Amplification and sequencing of ITR–AAVS1 junctions. Human primary
amniocytes and keratinocytes were infected at an m.o.i. of 20 withMOLECULAR THERAPY Vol. 10, No. 4, October 2004
Copyright C The American Society of Gene TherapyAR1-CMVRepTS and/or AR1-TKRepTS virus and harvested 5 days after
infection. Site-specific integration was determined by PCR of total
genomic DNA by using nested primer pairs specific for the right AAV
ITR (16s, 5V-GTAGCATGGCGGGTTAATCA-3V, and 17s, 5V-TTAAC-
TACAAGGAACCCCTAGTGATGG-3V) and the AAVS1 region (a, 5V-
GCCCCACTGCCGCAGCTGCTCCC-3V; b, 5V-CCGCACAGGCCGCCAG-
GAACTCG-3V; c, 5V-GCGCGQCAGAAGCCAGTAGAGC-3V; d, 5V-
CTGGCTCAGGTTCAGGAGAGG-3V; e, 5V-CGCTCAGAGGACAT-
CACGTG-3V; f, 5V-GGGACACAGGATCCCTGGAQGG-3V). Genomic DNAs
(500 ng) were preamplified in 50 Al of polymerase buffer with 2.5 U of
AmpliTaq Gold polymerase (Applied Biosystems, Roche, NJ, USA), 200
AM dNTPs, 1.5 mM MgCl2, and 300 nM each primer, and 1/100 of the
amplified DNA was used as template for a second round of PCR as
previously described [22]. Finally, one-tenth of the PCR product was
run on 1.5% agarose gel, transferred to Hybond N+ membrane, and
hybridized with AAVS1- or ITR-specific probes. The amplified junctions
were cloned into pCR 2.1-TOPO vector (Invitrogen, UK) and
sequenced.
Quantitative real-time PCR for determination of AAVS1-specific
integration. Quantitative real-time PCR of ITR-AAVS1 junctions in
primary keratinocytes and amniocytes was carried out by a two-step PCR
assay [34] with the ITR primer 17s, the AAVS1 primer e, and an AAVS1 5V
fluorescein-labeled probe (5V-TTTCCGGAGCACTTCCTTCTCG-3V) anneal-
ing to nucleotides 1612–1593 of the AAVS1. Quantitative real-time PCR of
ITR–AAVS1 junctions in AAVS1 transgenic mouse liver was carried out by
nested PCR with the ITR primers 16s and 17s, AAVS1 primers c and d, and a
fluorescent probe (5V-TCCTGGACTTQTGTCTCC-3V) annealing to nt 1125–
1141 of the AAVS1.
Mapping of non-AAVS1-specific integration sites. Integration junctions
were amplified, cloned, and sequenced by LM nested PCR [2] using two
nested AAV ITR-specific primers (18s, 5V-CCTAGTGATGGAGTTGGC-
CACTCC-3V, and 19s, 5V-GAGTTGGCCACTCCCTCTCTGC-3V). Human
DNA sequences were BLAST searched against the public database by the
Ensembl browser. Targeted gene search based on the chromosomal
localization of each integration site was done using the Human Contig
View of Ensembl.
Animal studies. Four- to 5-week-old female/male AAVS1 transgenic
mice [27] were injected iv with 2  108 tu of AR1CMVRepTS (group 1;
n = 4;) or AR1TKRepTS (group 2; n = 4) virus. Four mice (two from
each group) were given drinking water containing doxycycline at a
concentration of 200 Ag/ml. Two mice were injected iv with 2  108 or
109 tu of AR1, and one was mock infected. Site-specific integration was
determined by PCR on liver genomic DNA 12 days postinfection by
nested primer pairs specific for the right AAV ITR and the AAVS1
region (c and d). Livers were fixed in 4% paraformaldehyde, embedded
in OCT, frozen in liquid nitrogen-cooled isopentane, and cut into 10-
Am serial sections. Immunohistochemical staining for GFP was
performed using an avidin–biotin–peroxidase technique. The primary
antibody (a-GFP rabbit IgG fraction A-11122; Molecular Probes, Eugene,
OR, USA) and the biotinylated goat anti-rabbit secondary antibody
(Vectastain, Vector Laboratories) were diluted 1:1500 in PBS containing
0.1% Triton X-100 and 1% goat serum. Positive signals were detect by
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